Product image of Insuman Comb 25 (Insulin Human (Rdna)) supplied by GNH India

Insuman Comb 25

Active Ingredient:
Insulin Human (Rdna)
Origin:
EU

Insuman Comb 25 (Insulin Human (Rdna))

Insulin human (rDNA), the active ingredient in Insuman Comb 25, is an insulin presented as an injection solution for subcutaneous use. It treats type 1 and type 2 diabetes mellitus in patients requiring insulin therapy.

GNH India supplies Insuman Comb 25 as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Insuman Comb 25 is an insulin formulation used to manage blood glucose in diabetes mellitus and related hyperglycemic conditions.

  • Type 1 diabetes mellitus: provides basal and prandial insulin coverage to achieve target glycemic control.
  • Type 2 diabetes mellitus: used when oral agents are insufficient to maintain adequate glucose levels.
  • Diabetic ketoacidosis: administered as part of emergency insulin therapy to rapidly lower plasma glucose.

How It Works

  • Insulin human (rDNA) binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor tyrosine kinase pathway. This promotes translocation of GLUT4 transporters, enhancing glucose uptake, while simultaneously suppressing hepatic gluconeogenesis and glycogenolysis, leading to reduced blood glucose concentrations.

Side Effects

Insuman Comb 25 may cause a range of adverse reactions, most of which are related to its pharmacologic action or injection site.

Common Side Effects

  • Hypoglycemia: symptomatic low blood glucose levels.
  • Weight gain: increase in body mass due to improved glucose utilization.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Lipodystrophy: localized changes in subcutaneous fat.
  • Localized allergic reactions: mild rash or urticaria.

Serious or Rare Side Effects

  • Severe hypoglycemia leading to seizures or loss of consciousness.
  • Anaphylactic reaction: systemic allergic response requiring emergency care.
  • Edema: fluid retention causing swelling of extremities.
  • Hypokalemia: low serum potassium levels, especially with high insulin doses.

Precautions & Warnings

When using Insuman Comb 25, careful monitoring and patient education are essential to minimize risks.

  • Monitor blood glucose regularly: adjust dose based on self‑monitoring results.
  • Adjust dose during illness or stress: hyperglycemia may require temporary dose increase.
  • Use caution in renal impairment: reduced clearance can enhance hypoglycemic risk.
  • Avoid use in patients with known hypersensitivity to insulin human or its excipients.
  • Pregnancy and lactation: consult a healthcare professional before initiating therapy.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Insuman Comb 25 can interact with several drug classes, affecting glycemic control or masking symptoms.

Major Interactions (Avoid)

  • Sulfonylureas: additive hypoglycemic effect may cause severe low blood glucose.
  • Beta‑blockers: may mask typical hypoglycemia warning signs such as tachycardia.
  • MAO inhibitors: potential for enhanced insulin action and hypoglycemia.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: may increase insulin sensitivity, requiring dose adjustment.
  • Thiazide diuretics: can raise blood glucose, possibly necessitating higher insulin doses.
  • Oral contraceptives: hormonal changes may alter insulin requirements.

Frequently Asked Questions

Insuman Comb 25 is a recombinant human insulin preparation indicated for the management of blood glucose in patients with type 1 or type 2 diabetes mellitus, including use in emergency situations such as diabetic ketoacidosis when oral agents are insufficient.

Insulin human (rDNA) mimics natural insulin by binding to insulin receptors on muscle, fat and liver cells. This triggers intracellular signaling that increases glucose uptake, promotes glycogen synthesis, and suppresses hepatic glucose production, thereby lowering circulating blood glucose levels.

The dose of Insuman Comb 25 is individualized. A qualified prescriber determines the amount, timing and frequency based on the patient’s age, weight, glycemic targets, dietary intake and response to therapy.

Insulin is generally considered the preferred glucose‑lowering therapy in pregnancy and lactation because it does not cross the placenta in harmful amounts. However, treatment should be guided by a healthcare professional who can balance maternal glucose control with fetal safety.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain where required) and import documentation.

Insuman Comb 25 contains recombinant human insulin, offering a predictable pharmacokinetic profile similar to other short‑acting and intermediate‑acting human insulins. Compared with rapid‑acting insulin analogues, it may have a slightly slower onset but provides reliable basal and prandial coverage at a competitive cost.

Insuman Comb 25 should be stored in a refrigerator between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Once in use, it may be kept at controlled room temperature for up to 28 days, as indicated on the label.

The product is supplied as an injectable solution for subcutaneous administration. It is typically injected into the abdomen, thigh or upper arm using a sterile needle or pen device, following the dosing schedule prescribed by the treating clinician.

The most serious risks include severe hypoglycemia, which can lead to seizures or loss of consciousness, and rare systemic allergic reactions such as anaphylaxis. Prompt recognition and appropriate medical intervention are essential if these events occur.

Patients with a documented hypersensitivity to recombinant human insulin or any excipients in the formulation should avoid using Insuman Comb 25. Additionally, it is contraindicated in individuals experiencing hypoglycemia until glucose levels are normalized.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human (Rdna)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT